Mesenchymal Stem Cells Migration Homing and Tracking

Sohni, Abhishek; Verfaillie, Catherine M.

doi:10.1155/2013/130763

Cited by 350 publications

(303 citation statements)

References 105 publications

Supporting

Mentioning

291

Contrasting

Unclassified

Order By: Relevance

“…The peripheral approach is based on key properties of MSCs including delivery of the cells ''homing'' to the site of injury. Interestingly, migration and homing are influenced by multiple factors including age, passage, and number of cells, culture conditions, and delivery method [40]. This migration and homing potential without tumorigenic potential has been described in different disease [41,42] and in BPD models previously [38,43].…”

Section: Mscs and Bpdmentioning

confidence: 99%

Stem cells and Bronchopulmonary Dysplasia - The five questions: Which cells, when, in which dose, to which patients via which route?

Mueller

Kramer

2017

Paediatric Respiratory Reviews

View full text Add to dashboard Cite

Section: Mscs and Bpdmentioning

confidence: 99%

Stem cells and Bronchopulmonary Dysplasia - The five questions: Which cells, when, in which dose, to which patients via which route?

Mueller

Kramer

2017

Paediatric Respiratory Reviews

View full text Add to dashboard Cite

“…Following transplantation, MSCs target and migrate to the site of injury. In some cases these cells respond to the local environment with appropriate secretion of soluble factors to ameliorate inflammation and promote repair [30] . This paracrine mechanism offers potential in ASD treatment.…”

Section: Mesenchymal Stem Cells In Treating Autism: the Rationalementioning

confidence: 99%

Mesenchymal stem cells in treating autism: Novel insights

Siniscalco

Bradstreet

Sych

et al. 2014

WJSC

View full text Add to dashboard Cite

Autism spectrum disorders (ASDs) are complex neurodevelopmental disorders characterized by dysfunctions in social interactions, abnormal to absent verbal communication, restricted interests, and repetitive stereotypic verbal and non-verbal behaviors, influencing the ability to relate to and communicate. The core symptoms of ASDs concern the cognitive, emotional, and neurobehavioural domains. The prevalence of autism appears to be increasing at an alarming rate, yet there is a lack of effective and definitive pharmacological options. This has created an increased sense of urgency, and the need to identify novel therapies. Given the growing awareness of immune dysregulation in a significant portion of the autistic population, cell therapies have been proposed and applied to ASDs. In particular, mesenchymal stem cells (MSCs) possess the immunological properties which make them promising candidates in regenerative medicine. MSC therapy may be applicable to several diseases associated with inflammation and tissue damage, where subsequent regeneration and repair is necessary. MSCs could exert a positive effect in ASDs through the following mechanisms: stimulation of repair in the damaged tissue, e.g. , inflammatory bowel disease; synthesizing and releasing anti-inflammatory cytokines and survival-promoting growth factors; integrating into existing neural and synaptic network, and restoring plasticity. The paracrine mechanisms of MSCs show interesting potential in ASD treatment. Promising and impressive results have been reported from the few clinical studies published to date, although the exact mechanisms of action of MSCs in ASDs to restore functions are still largely unknown. The potential role of MSCs in mediating ASD recovery is discussed in light of the newest findings from recent clinical studies.

show abstract

“…8,12 Homing of transplanted stem cells to the targeted tissues depend on various factors such as the cell conditions, the host conditions and the delivery method. 15 Our previous study showed that direct injection of ASCs into injured myocardium signicantly increased le ventricular ejection fraction and reduced infarct size of infarcted rat hearts. 12 Therefore, we believe that ASCs is an effective candidate for treating congestive heart failure and other degenerative diseases.…”

Section: Introductionmentioning

confidence: 99%

Selection of chemotactic adipose-derived stem cells using a microfluidic gradient generator

et al. 2015

View full text Add to dashboard Cite

Vous avez des questions? Nous pouvons vous aider. Pour communiquer directement avec un auteur, consultez la première page de la revue dans laquelle son article a été publié afin de trouver ses coordonnées. Si vous n'arrivez pas à les repérer, communiquez avec nous à PublicationsArchive-ArchivesPublications@nrc-cnrc.gc.ca. Questions? Contact the NRC Publications Archive team atPublicationsArchive-ArchivesPublications@nrc-cnrc.gc.ca. If you wish to email the authors directly, please see the first page of the publication for their contact information. NRC Publications Archive Archives des publications du CNRCThis publication could be one of several versions: author's original, accepted manuscript or the publisher's version. / La version de cette publication peut être l'une des suivantes : la version prépublication de l'auteur, la version acceptée du manuscrit ou la version de l'éditeur. For the publisher's version, please access the DOI link below./ Pour consulter la version de l'éditeur, utilisez le lien DOI ci-dessous.http://doi.org/10.1039/C4RA12863JAccess and use of this website and the material on it are subject to the Terms and Conditions set forth at Selection of chemotactic adipose-derived stem cells using a microfluidic gradient generator Natarajan, Kanmani; Tian, Chantal; Xiang, Bo; Chi, Chao; Deng, Jixian; Zhang, Rundi; Freed, Darren H.; Arora, Rakesh C.; Tian, Ganghong; Lin, Francis http://nparc.cisti-icist.nrc-cnrc.gc.ca/fra/droits L'accès à ce site Web et l'utilisation de son contenu sont assujettis aux conditions présentées dans le site LISEZ CES CONDITIONS ATTENTIVEMENT AVANT D'UTILISER CE SITE WEB. NRC Publications Record / Notice d'Archives des publications de CNRC:http://nparc.cisti-icist.nrc-cnrc.gc.ca/eng/view/object/?id=3039e115-086c-46b1-89a1-b836cdb08b31 http://nparc.cisti-icist.nrc-cnrc.gc.ca/fra/voir/objet/?id=3039e115-086c-46b1-89a1-b836cdb08b31Selection of chemotactic adipose-derived stem cells using a microfluidic gradient generator † Kanmani Natarajan, ab Chantal Tian, a Bo Xiang, cd Chao Chi, def Jixian Deng, df Rundi Zhang, a Darren H. Freed, g Rakesh C. Arora, h Ganghong Tian * df and Francis Lin * abij Stem cells hold great promise for treating various degenerative diseases and conditions. However, the outcomes of preclinical and clinical cell therapy studies are still not close to our expectation. We believe that the unsatisfactory outcomes of cell therapy are at least partially due to insufficient homing of implanted stem cells into target organs and the use of heterogeneous cell populations for cell therapy.Therefore, there is a need to develop an effective guiding technique for stem cells to migrate to the target organs and to isolate effective stem cell populations. Toward this direction, we have previously demonstrated chemotaxis of rat adipose-derived stem cells (ASCs) to a well-defined gradient of epidermal growth factor (EGF) using a microfluidic device. In the current study, we further developed a microfluidics-based method for selecting chemotactic ASCs to EGF. This meth...

show abstract

Mesenchymal Stem Cells Migration Homing and Tracking

Cited by 350 publications

References 105 publications

Stem cells and Bronchopulmonary Dysplasia - The five questions: Which cells, when, in which dose, to which patients via which route?

Stem cells and Bronchopulmonary Dysplasia - The five questions: Which cells, when, in which dose, to which patients via which route?

Mesenchymal stem cells in treating autism: Novel insights

Selection of chemotactic adipose-derived stem cells using a microfluidic gradient generator

Contact Info

Product

Resources

About